Get the Stockscreener App
96.74
0.65%
-0.1626
Agilon Health Inc stock is traded at $96.74, with a volume of 144.08K.
It is down -0.65% in the last 24 hours and down -25.85% over the past month.
Agilon Health Inc is a healthcare services company that partners with primary care physicians to support value-based care for senior patients. The company provides a platform that enables physician groups to manage healthcare outcomes and costs through a Medicare-centric, capitated care model and long-term partnerships with community-based physicians.
See More
Previous Close:
$96.90
Open:
$96.21
24h Volume:
144.08K
Relative Volume:
0.42
Market Cap:
$1.62B
Revenue:
$5.82B
Net Income/Loss:
$-373.54M
P/E Ratio:
-4.2907
EPS:
-22.546
Net Cash Flow:
$-87.01M
1W Performance:
-0.53%
1M Performance:
-25.85%
6M Performance:
+988.73%
1Y Performance:
+246.92%
1-Day Range:
$92.66
$97.00
1-Week Range:
$85.90
$101.80
52-Week Range:
$7.48
$133.04
Agilon Health Inc Stock (AGL) Company Profile
Name
Agilon Health Inc
Sector
Industry
Phone
562-256-3800
Address
440 POLARIS PARKWAY, WESTERVILLE
Compare AGL vs HCA, THC, FMS, EHC, DVA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGL
Agilon Health Inc
|
96.74 | 1.63B | 5.82B | -373.54M | -87.01M | -22.55 |
HCA
Hca Healthcare Inc
|
405.74 | 87.61B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
265.90 | 21.57B | 21.46B | 2.65B | 3.35B | 19.23 |
FMS
Fresenius Medical Care Ag Adr
|
23.52 | 12.65B | 22.44B | 1.35B | 2.03B | 1.9002 |
EHC
Encompass Health Corp
|
122.13 | 12.19B | 6.07B | 793.80M | 464.40M | 5.9914 |
DVA
Davita Inc
|
176.50 | 11.49B | 13.84B | 1.10B | 1.49B | 10.42 |
Agilon Health Inc Stock (AGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Aug-06-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-25-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-08-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-10-25 | Upgrade | Citigroup | Sell → Neutral |
| Jan-10-25 | Initiated | Needham | Hold |
| Dec-16-24 | Initiated | Macquarie | Neutral |
| Dec-11-24 | Initiated | Bernstein | Mkt Perform |
| Nov-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Nov-08-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-30-24 | Downgrade | Citigroup | Neutral → Sell |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Underperform |
| May-30-24 | Initiated | Robert W. Baird | Neutral |
| Apr-22-24 | Initiated | Citigroup | Neutral |
| Mar-06-24 | Initiated | Barclays | Underweight |
| Feb-26-24 | Downgrade | Jefferies | Buy → Hold |
| Feb-26-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Jan-08-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-08-24 | Downgrade | Stifel | Buy → Hold |
| Jan-08-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-05-24 | Downgrade | Truist | Buy → Hold |
| Dec-11-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-06-23 | Initiated | JMP Securities | Mkt Outperform |
| Nov-21-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-20-23 | Initiated | The Benchmark Company | Buy |
| Jun-13-23 | Initiated | Evercore ISI | In-line |
| Dec-09-22 | Initiated | Stifel | Buy |
| Sep-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-22 | Initiated | Goldman | Buy |
| Sep-07-22 | Resumed | Truist | Buy |
| Jun-24-22 | Initiated | BTIG Research | Neutral |
| Mar-30-22 | Initiated | Guggenheim | Buy |
| Oct-20-21 | Initiated | Jefferies | Buy |
| Sep-27-21 | Initiated | SVB Leerink | Outperform |
| Sep-10-21 | Initiated | Cowen | Outperform |
| May-11-21 | Initiated | William Blair | Outperform |
| May-10-21 | Initiated | BofA Securities | Buy |
| May-10-21 | Initiated | Deutsche Bank | Buy |
| May-10-21 | Initiated | Goldman | Buy |
| May-10-21 | Initiated | JP Morgan | Overweight |
| May-10-21 | Initiated | Truist | Buy |
| May-10-21 | Initiated | Wells Fargo | Overweight |
| May-10-21 | Initiated | Wolfe Research | Outperform |
View All
Agilon Health Inc Stock (AGL) Latest News
Agilon Health, Inc. (NYSE:AGL) Receives Consensus Rating of "Hold" from Brokerages - marketbeat.com
Agilon Health (AGL) Q2 2026 Earnings Call Transcript - aol.com
Agilon Health Inc (AGL) Stock Up 9.0% but GF Value Says Overvalued -- GF Score: 71/100 - GuruFocus
Agilon Health (NYSE:AGL) Trading 8.5% HigherHere's What Happened - marketbeat.com
Should agilon health’s (AGL) Profit Rebound and Higher Guidance Prompt a Fresh Look From Investors? - simplywall.st
AGL|agilon health inc|Price:89.299|Chg%:+3.039 - TradingKey
5 Insightful Analyst Questions From agilon health’s Q2 Earnings Call - Yahoo Finance
Agilon Health (NYSE:AGL) Valuation Debate Grows After Guidance - Kalkine Media
Why Is AGL Stock Rising Today? - Stocktwits
Has Agilon Health (AGL) Outpaced Other Medical Stocks This Year? - Yahoo Finance
AQR Capital discloses 4.15% agilon health (AGL) stake in Schedule 13G/A - Stock Titan
Is Agilon Health Inc (AGL) a Bargain After 10.7% Drop? GF Value Says Undervalued - GuruFocus
Goldman Sachs Group (AGL) discloses 3.9% beneficial stake in agilon health - Stock Titan
Citigroup Upgrades Agilon Health to Neutral From Sell, Adjusts Price Target to $115 From $105 - marketscreener.com
Citi Maintains Agilon Health(AGL.US) With Hold Rating, Maintains Target Price $115 - Moomoo
AGILON HEALTH, INC. : CITIGROUP RAISES TO NEUTRAL FROM SELL; RAISES TARGET PRICE TO $115 FROM $105 - Bitget
Agilon Health (AGL) Short Interest & Short Float | Updated Aug 2026 $AGL - marketbeat.com
Citi Upgrades Agilon Health(AGL.US) to Hold Rating, Raises Target Price to $115 - Moomoo
Weekly Recap: Cash, debt & guidance and CHF rollout, clinical expansion - TradingView
Agilon Health Earnings Call Signals Profitable Turnaround - The Globe and Mail
TD Cowen Maintains Agilon Health(AGL.US) With Hold Rating, Raises Target Price to $95 - Moomoo
Can agilon health (AGL) Justify Its Valuation As Earnings Turned Profitable? - Yahoo Finance
agilon health: The Q2 Inflection Is Real (NYSE:AGL) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Agilon Health (AGL), Qiagen (QGEN) and Coherus Biosciences (CHRS) - The Globe and Mail
A Quick Look at Today's Ratings for Agilon Health(AGL.US), With a Forecast Between $105 to $140 - Moomoo
Baird Maintains Agilon Health(AGL.US) With Hold Rating, Raises Target Price to $116 - Moomoo
Evercore Maintains Agilon Health(AGL.US) With Hold Rating, Raises Target Price to $125 - Moomoo
agilon health, inc. Stock 12‑Month Price Target Raised to $106.69, Implies 1% Downside - TradingView
Agilon Health (NYSE:AGL) Trading Down 9.9%What's Next? - MarketBeat
agilon health (AGL) Is Up 16.4% After Q2 Return To Profitability And Raised 2026 Outlook - simplywall.st
A Quick Look at Today's Ratings for Agilon Health(AGL.US), With a Forecast Between $105 to $125 - Moomoo
Agilon Health Q2 Earnings Call Highlights - TradingView
AGILON HEALTH, INC. : BENCHMARK RAISES TARGET PRICE TO $140 FROM $95 - Moomoo
Earnings call transcript: Agilon Health tops Q2 2026 estimates and lifts outlook - Investing.com
Agilon Health (AGL) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance
Agilon (AGL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
agilon health, inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Agilon Health (NYSE:AGL) Releases Earnings Results, Beats Estimates By $0.92 EPS - MarketBeat
Agilon: Q2 Earnings Snapshot - Barchart.com
Agilon Health tops Q2 estimates, raises 2026 guidance; Shares gain 3% - Investing.com South Africa
AGL Stock Jumps As Wells Fargo Doubles Price Target - StocksToTrade
(AGL) agilon health, inc. Expects Q3 Revenue Range $1.45B$1.48B - marketscreener.com
agilon health, inc. 2026: Revenue $1.49B, EPS $1.04— 10-Q Summary - TradingView
Earnings Flash (AGL) agilon health, inc. Reports Q2 Revenue $1.5B, vs. FactSet Est of $1.45B - marketscreener.com
agilon health (NYSE:AGL) Beats Q2 CY2026 Sales Expectations, Full-Year Sales Guidance is Optimistic - Barchart.com
Agilon Health Q2 revenue beats estimates, raises outlook - TradingView
agilon health Q2 2026: Revenue $1.49B, Gross Profit $107M, Adjusted EBITDA $70M - TradingView
[10-Q] agilon health, inc. Quarterly Earnings Report - Stock Titan
Agilon Health Inc. (AGL) Tops Q2 EPS by 96c ; Offers Guidance - StreetInsider
BRIEF-Agilon Health Q2 Revenue USD 1,490 Million Vs. IBES Estimate USD 1,448 Million - TradingView
Agilon Health, Inc. Increases Earnings Guidance for the Fiscal Year Ending December 31, 2026 - marketscreener.com
Agilon Health Inc Stock (AGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):